Marco Marchetti | Director of the National Center for Health Technology Assessment
Istituto Superiore di Sanita

Marco Marchetti, Director of the National Center for Health Technology Assessment, Istituto Superiore di Sanita

  Marco Marchetti has graduated in medicine at Università Cattolica del Sacro Cuore ( Rome ) and postgraduate in Hygiene and Public Health and Legal Medicine.
Since January 1, 2017 he is the Director of the National Center for the 'Health Technology Assessment of the Italian National Institute for Health.1
He continues to collaborate with the Health Technology Assessment (HTA) and Innovation Unit of the Fondazione Policlinico Universitario “Agostino Gemelli”, Università Cattolica del Sacro Cuore.
He has been Director of Health Technology Assessment and Innovation Unit until December 2016.
He is also the European Director of the International Master Program in HTA and Management since 2001 (http://www.ulyssesprogram.net/ ).
He has been in the period 2007-2015 Director of Scientific-Technical Office of Institutional review board (IRB) - Ethical review board of the Università Cattolica del Sacro Cuore .
He has been experts and referees for Health Technology research proposal in the year 2003 and 2008 by The NHS Health Technology Assessment Programme. - National Coordinating Office for Health Technology Assessment - UK.
He was in charge to organize the HTAi international 2nd annual meeting “ Bringing HTA into practice”, 20-22 June 2005.
He has been the Co-Chair of Local Organizing Committee of the 2017 Health Technology Assessment Meeting in Rome in the next June 2017.
He co-chair of Interest Subgroups of HTA international – Htai www.htai.org - “Hospital based HTA”.
He participates since the beginning to the activities of the European Network of Health Technology Assessment (http://www.eunethta.eu/ ).
His expertise area are on the following fields: hospital management, quality assurance, risk management, HTA, drug epidemiology, evidence based medicine, digital medicine impact evaluation.
He has collaborate with the National Agency for Drugs and Regional Government in the assessment process of different drugs and medical devices with a particular focus on innovative pricing scheme and payment by results.
He published more than 150 paper on national and international on the subject he interested in.
National Institute for Health is supporting Italian National Health Care System from a scientific and technical point of view.

Appearances:



Day Two World Pharma Pricing & Market Access EU Congress @ 12:05

ROUNDTABLES

How to use RWE for post-marketing of new drugs

back to speakers